Remove tag combination-product-development
article thumbnail

Generative AI with Google Lens to detect counterfeits in pharma

Express Pharma

Combining generative AI and image recognition is probably the answer. I’d want to make a recommendation for pharma companies, government officials, and customers to combine the strength of AI with picture recognition to create a foolproof way to restrict the risks connected with counterfeit drugs. *In System workflow 1.

article thumbnail

Biotech titans Bengaluru and Hyderabad fortify India’s dominance

Express Pharma

Life science research and development in India is increasing substantially, driven by a combination of government initiatives, a skilled workforce, and continued investments. By developing ‘Covaxin’, India’s first indigenous COVID-19 vaccine, it is sprinting towards a tag for innovation too.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Actualising the power of antibody-drug conjugates as cancer therapeutics

European Pharmaceutical Review

An ADC combines the specificity of an antibody and the potent power of an anti?cancer In total, there are 14 approved ADCs on the global market, all for oncology indications, and over 140 ADCs currently in clinical development. generation products from fully delivering on their initial promise. Finding the right combination.

article thumbnail

How automation can help to address supply chain challenges in pharma

pharmaphorum

Supply chain issues have been rife in pharmaceuticals for a while, but current socio-economic challenges such as the conflict in Ukraine and the COVID-19 pandemic have led to extended wait times and higher prices for thousands of products. Automation can be such a solution. Reducing capacity issues. Cutting down on safety stock.

article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

Combining data from all markets, efficacy-related needs were identified as the most important unmet needs category. Although a subset of patients derives long-term benefits from IO therapies, a high percentage of patients still fail to respond or develop resistance to IO therapy. Cost-related unmet needs also scored highly.

article thumbnail

Patent wars: what’s behind Amgen’s possible win over Sanofi at the US Supreme Court

Pharmaceutical Technology

Developed by Sanofi and Regeneron, Praluent was approved by the FDA in July 2015. Both drugs come with a high price tag. On the opposing side, Sanofi argues that Amgen’s approach not only violates enablement requirements, but also stifles innovation by stopping others from developing new therapeutics, says Falati.

104
104
article thumbnail

Gilead tags Merck for first-line triple negative breast cancer trial

pharmaphorum

Trodelvy has already established itself as a go-to therapy for TNBC patients whose disease has progressed after prior treatments, says Gilead, while Keytruda is approved as a first-line therapy for the cancer in combination with chemotherapy, in patients with PD-L1 scores of 10 or more. While its headline revenue of $7.4